Akoya Biosciences Net Worth
Akoya Biosciences Net Worth Breakdown | AKYA |
Akoya Biosciences Net Worth Analysis
Akoya Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Akoya Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Akoya Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Akoya Biosciences' net worth analysis. One common approach is to calculate Akoya Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Akoya Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Akoya Biosciences' net worth. This approach calculates the present value of Akoya Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Akoya Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Akoya Biosciences' net worth. This involves comparing Akoya Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Akoya Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Akoya Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Akoya Biosciences' net worth research are outlined below:
| Akoya Biosciences appears to be risky and price may revert if volatility continues | |
| Akoya Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 96.63 M. Net Loss for the year was (63.32 M) with profit before overhead, payroll, taxes, and interest of 43.39 M. | |
| Akoya Biosciences currently holds about 87.61 M in cash with (50.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31. | |
| Akoya Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Is Akoya Biosciences Using Too Much Debt |
Akoya Biosciences Quarterly Good Will |
|
Akoya Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Akoya Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akoya Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Akoya Biosciences Target Price Consensus
Akoya target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Akoya Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Buy |
Most Akoya analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Akoya stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Akoya Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAkoya Biosciences Target Price Projection
Akoya Biosciences' current and average target prices are 3.21 and 13.13, respectively. The current price of Akoya Biosciences is the price at which Akoya Biosciences is currently trading. On the other hand, Akoya Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Akoya Biosciences Market Quote on 13th of November 2024
Target Price
Analyst Consensus On Akoya Biosciences Target Price
Know Akoya Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akoya Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akoya Biosciences backward and forwards among themselves. Akoya Biosciences' institutional investor refers to the entity that pools money to purchase Akoya Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-06-30 | 209.7 K | Bridgeway Capital Management, Llc | 2024-06-30 | 179.6 K | Charles Schwab Investment Management Inc | 2024-06-30 | 175.9 K | Gsa Capital Partners Llp | 2024-06-30 | 165.8 K | Osterweis Capital Management Inc | 2024-06-30 | 126.1 K | Bank Of New York Mellon Corp | 2024-06-30 | 67.5 K | Squarepoint Ops Llc | 2024-06-30 | 65.9 K | Zeliff Wallace Jackson Invst Counsel Inc | 2024-09-30 | 45.3 K | Jane Street Group Llc | 2024-06-30 | 44.7 K | Blue Water Life Science Advisors, Llc | 2024-06-30 | 4.7 M | Blackrock Inc | 2024-06-30 | 1.5 M |
Follow Akoya Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 159.39 M.Market Cap |
|
Project Akoya Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (1.18) | (1.24) |
When accessing Akoya Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Akoya Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Akoya Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Akoya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akoya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akoya Biosciences' management manipulating its earnings.
Evaluate Akoya Biosciences' management efficiency
Akoya Biosciences has return on total asset (ROA) of (0.1809) % which means that it has lost $0.1809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.282) %, meaning that it created substantial loss on money invested by shareholders. Akoya Biosciences' management efficiency ratios could be used to measure how well Akoya Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 13, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.41. At present, Akoya Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 59.4 M, whereas Total Assets are forecasted to decline to about 157.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.21 | 0.91 | |
| Tangible Book Value Per Share | 0.41 | 0.43 | |
| Enterprise Value Over EBITDA | (4.65) | (4.89) | |
| Price Book Value Ratio | 4.03 | 4.85 | |
| Enterprise Value Multiple | (4.65) | (4.89) | |
| Price Fair Value | 4.03 | 4.85 | |
| Enterprise Value | 219.4 M | 394 M |
The strategic vision of Akoya Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Enterprise Value Revenue 2.1334 | Revenue 93.2 M | Quarterly Revenue Growth (0.01) | Revenue Per Share 1.889 | Return On Equity (1.28) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akoya Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akoya Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akoya Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akoya Biosciences Corporate Filings
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 4th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 3rd of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Akoya Biosciences Earnings Estimation Breakdown
The calculation of Akoya Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Akoya Biosciences is estimated to be -0.2 with the future projection ranging from a low of -0.26 to a high of -0.16. Please be aware that this consensus of annual earnings estimates for Akoya Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.26 Lowest | Expected EPS | -0.16 Highest |
Akoya Biosciences Earnings Projection Consensus
Suppose the current estimates of Akoya Biosciences' value are higher than the current market price of the Akoya Biosciences stock. In this case, investors may conclude that Akoya Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Akoya Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of September 2024 | Current EPS (TTM) | |
| 0 | 83.6% | -0.27 | -0.2 | -1.17 |
Akoya Biosciences Earnings History
Earnings estimate consensus by Akoya Biosciences analysts from Wall Street is used by the market to judge Akoya Biosciences' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Akoya Biosciences' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Akoya Biosciences Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Akoya Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Akoya Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Akoya Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Akoya Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Akoya Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Akoya Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Akoya Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Akoya Biosciences should always be considered in relation to other companies to make a more educated investment decision.Akoya Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Akoya Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-05 | 2024-06-30 | -0.27 | -0.27 | 0.0 | 0 | ||
2024-05-13 | 2024-03-31 | -0.29 | -0.48 | -0.19 | 65 | ||
2024-03-04 | 2023-12-31 | -0.27 | -0.22 | 0.05 | 18 | ||
2023-11-08 | 2023-09-30 | -0.37 | -0.26 | 0.11 | 29 | ||
2023-08-07 | 2023-06-30 | -0.44 | -0.46 | -0.02 | 4 | ||
2023-05-08 | 2023-03-31 | -0.48 | -0.49 | -0.01 | 2 | ||
2023-03-06 | 2022-12-31 | -0.43 | -0.5 | -0.07 | 16 | ||
2022-11-07 | 2022-09-30 | -0.44 | -0.47 | -0.03 | 6 | ||
2022-08-08 | 2022-06-30 | -0.37 | -0.47 | -0.1 | 27 | ||
2022-05-05 | 2022-03-31 | -0.39 | -0.44 | -0.05 | 12 | ||
2022-03-14 | 2021-12-31 | -0.31 | -0.47 | -0.16 | 51 | ||
2021-11-08 | 2021-09-30 | -0.26 | -0.31 | -0.05 | 19 | ||
2021-08-10 | 2021-06-30 | -0.23 | -0.2 | 0.03 | 13 | ||
2021-05-18 | 2021-03-31 | -0.17 | -3.54 | -3.37 | 1982 | ||
2021-03-03 | 2020-12-31 | 0 | -0.205 | -0.205 | 0 |
Akoya Biosciences Corporate Management
| Clifford Hoyt | VP Affairs | Profile | |
| Marilee MBA | Chief Officer | Profile | |
| Jennifer Kamocsay | General Counsel | Profile | |
| Nikolay Samusik | CoFounder | Profile | |
| Priyam Shah | Senior Strategy | Profile |
Already Invested in Akoya Biosciences?
The danger of trading Akoya Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akoya Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akoya Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akoya Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Revenue Per Share 1.889 | Quarterly Revenue Growth (0.01) | Return On Assets (0.18) | Return On Equity (1.28) |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.